Announcing the 2024 Harvard President’s Innovation Challenge Finalists
Bullseye Biosciences (Harvard Kenneth C. Griffin Graduate School of Arts and Sciences): Transforming therapeutic protein design to expedite the development of life-saving medicines.
Ilios Therapeutics (Harvard Business School, Harvard Kennedy School): Developing multi-target molecules to counter neurodegenerative diseases.
Promakhos Therapeutics (Harvard Kenneth C. Griffin Graduate School of Arts and Sciences, Harvard Medical School): Focusing on local and controlled modulation of the immune system to restore homeostasis.
Somite.ai (Harvard Medical School): Developing drugs for previously inaccessible diseases with an AI-powered platform for cell replacement therapy.
Stratagen Bio (Harvard Business School): Transforming MRI into a tool for objective clinical decision making and quantitative biomarker assessment.